Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi-Synthelabo Groupe
Woman and Man Max 99 years
Sanofi-Synthelabo Groupe
Update Il y a 4 ans
a double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral disease (PAD) patient receiving a unilateral below knee by-pass graft
To evaluate whether clopidogrel 75 mg o.d. versus placebo (on a background of ASA 75-100 mg/d) will lead to an increased rate of primary patency, limb salvage and survival, in patients receiving a bel...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Sanofi-Synthelabo Groupe
Update Il y a 4 ans
A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy
The primary objective of the study is to compare progression-free survival (PSA progression after systemic treatment, radiologically or histologically documented progression after systemic treatment o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Groupe
Update Il y a 4 ans
Estudio aleatorizado, doble ciego, de dos brazos, controlado con placebo y de 12 meses de duración de los efectos de rimonabant 20 mg una vez al día sobre la cantidad y actividad de la grasa visceral en pacientes con obesidad abdominal y síndrome metabólico. A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20 mg once daily on the amount and the activity of visceral fat in abdominally obese patients with metabolic syndrome
Evaluar el efecto del rimonabant sobre el area grasa visceral durante un periodo de 12 meses al ser administrado con una dieta hipocalórica moderada a pacientes con obesidad abdominal y síndrome meta...
Country
None
organs
None
Specialty
None
unknown
More information